214 related articles for article (PubMed ID: 22348914)
1. Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia.
Haddley K
Drugs Today (Barc); 2011 Dec; 47(12):891-901. PubMed ID: 22348914
[TBL] [Abstract][Full Text] [Related]
2. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
[TBL] [Abstract][Full Text] [Related]
3. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
4. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
Gelsinger C; Steinhagen-Thiessen E; Kassner U
Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
7. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
8. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
Toth PP
J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein B antisense inhibition--update on mipomersen.
Gebhard C; Huard G; Kritikou EA; Tardif JC
Curr Pharm Des; 2013; 19(17):3132-42. PubMed ID: 23317401
[TBL] [Abstract][Full Text] [Related]
10. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
[TBL] [Abstract][Full Text] [Related]
11. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.
Reeskamp LF; Kastelein JJP; Moriarty PM; Duell PB; Catapano AL; Santos RD; Ballantyne CM
Atherosclerosis; 2019 Jan; 280():109-117. PubMed ID: 30500603
[TBL] [Abstract][Full Text] [Related]
13. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N; Hegele RA
Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
[TBL] [Abstract][Full Text] [Related]
14. Mipomersen.
Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
[TBL] [Abstract][Full Text] [Related]
15. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
17. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
[TBL] [Abstract][Full Text] [Related]
18. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
Vogt A; Parhofer KG
Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
[TBL] [Abstract][Full Text] [Related]
19. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
Ricotta DN; Frishman W
Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
[TBL] [Abstract][Full Text] [Related]
20. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
